Related Experiment Video
Updated: Jul 5, 2026
07:31
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
C-erbB-2 expression and prognostic significance in osteosarcoma.
Bilgehan Yalçin1, Gökhan Gedikoğlu, Tezer Kutluk
1Department of Pediatric Oncology, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey. yalcinb@hacettepe.edu.tr
Pediatric Blood & Cancer
|April 19, 2008
Summary
C-erbB-2 overexpression in osteosarcoma (OST) did not correlate with metastatic potential. This study found no independent prognostic significance, suggesting therapies targeting c-erbB-2 may not benefit OST patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- C-erbB-2 is a potential prognostic marker for osteosarcoma (OST).
- Investigating c-erbB-2 expression and its prognostic significance in OST is crucial for treatment strategies.
Purpose of the Study:
- To determine the prognostic significance of c-erbB-2 expression in osteosarcoma.
- To evaluate the correlation between c-erbB-2 status and patient survival outcomes.
Main Methods:
- Immunohistochemical (IHC) staining using CB11 antibody on 79 pre-treatment osteosarcoma biopsies.
- Analysis of c-erbB-2 expression in relation to clinical variables and survival rates.
Main Results:
- 45.6% of osteosarcoma cases showed positive c-erbB-2 staining.
- No significant association found between c-erbB-2 expression and metastasis, gender, age, tumor size, or tumor site.
- Five-year event-free survival (EFS) and overall survival (OS) were significantly lower in c-erbB-2 positive cases (EFS: 22.4%, OS: 32.3%) compared to negative cases (EFS: 50%, OS: 62.1%).
- Tumor size <10 cm was associated with significantly higher 5-year EFS and OS rates.
- Cox regression analysis identified tumor size, not c-erbB-2 expression, as an independent prognostic factor for EFS.
Conclusions:
- C-erbB-2 overexpression in osteosarcoma is not linked to metastatic potential.
- C-erbB-2 expression status lacks independent prognostic significance in osteosarcoma.
- Current findings do not support the use of targeted therapies directed at c-erbB-2 for osteosarcoma treatment.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...